This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Warren E. Buffett, 2008
Allayannis, George (Yiorgos)Case DARDEN-F-1550-EFinanceIn January 2008, in the midst of the subprime-mortgage crisis, Warren Buffett is looking for good investment opportunities for his almost $50 billion in cash. As usual, he has been patient and careful in identifying the right opportunities; however, the amount of cash in his company has grown considerably, and with so much cash sitting idle, returns could suffer. This case can be used to pursue several objectives: (1) to showcase Warren Buffett’s...Starting at €8.20
-
Warren E. Buffett, 2008 - Teaching Note
Allayannis, George (Yiorgos)Teaching Note DARDEN-F-1550TN-EFinanceTeaching note for product F-1550Starting at €0.00
-
New Leaders of Financial Giants: The Cases of Vikram Pandit (Citi) and John Thain (Merrill Lynch)
Allayannis, George (Yiorgos)Case DARDEN-F-1551-EFinanceIn January 2008, Citi and Merrill Lynch are trying to steer their ships back to calm waters. The new CEOs, Vikram Pandit (Citi) and John Thain (Merrill), have been at the helm of their companies for less than three months. This case focuses on their steps to counteract the massive losses resulting from their firms' investments in subprime-mortgage structures. What actions have these leaders taken thus far and what actions should they consider goi...Starting at €8.20
-
Deutsche Bank and the Road to Basel III
Allayannis, George (Yiorgos); Wicks, Andrew C.; Yemen, Gerry; Dougherty, MatthewCase DARDEN-F-1695-EFinanceThis public-sourced case was named the best finance case of 2013 in the 24th annual awards and competition sponsored by The Case Centre. It was designed for and works well in the latter portion of a GEMBA Financial Management and Policies course and in the early stage of a second-year MBA elective Financial Institutions and Markets course. The case is set in mid-2012 as the new co-CEOs of Deutsche Bank are about to speak in an analyst call. Stude...Starting at €8.20
-
Fintech, Payments Innovation, and the Acquisition of Worldpay
Allayannis, George (Yiorgos); Yemen, Gerry; Lane, DavidCase DARDEN-F-1829-EFinanceThis case uses the Vantiv, a US credit-card-processing company, acquisition of Worldpay, Britain’s largest payments processor, to discuss broader themes in the payment space. Payments are a crucial function of financial institutions because of their sheer volume and revenue potential. Fintech has enabled more ways for financial institutions and consumers to make payments and has the potential for significant disruption. The material in the case a...Starting at €8.20
-
Business Succession and the Asher Estate - Teaching Note
Stephen Sapp; Alykhan AlidinaTeaching Note IVEY-8B20N011-EFinanceTeaching note for product 9B20N011.Starting at €0.00
-
KTM - Venture Capitalist Exit
Stephen Sapp; Charlene Zietsma; Iris Fischlmayr; Rob WongCase IVEY-9B07N003-EEntrepreneurship, Finance, StrategyKTM is a small motorcycle manufacturing company located in Austria. As a result of difficult economic conditions in 1999, KTM went private with the help of the venture capital firm BC European Capital (BC). Following a couple of years of strong growth, BC is looking to liquidate its position and move on. KTM is faced with the decision of determining the best means to repurchase BC's equity position in the firm and leave the firm with enough finan...Starting at €8.20
-
Magna International and Dual Share Unification - Teaching Note
W. Glenn Rowe; Stephen Sapp; Nadine de Gannes; Abbas KhambatiTeaching Note IVEY-8B20M209-EStrategyTeaching note for product 9B20M209.Starting at €0.00
-
CanniMed Therapeutics: Acquiror or Target
Stephen Sapp; Shane FreedmanCase IVEY-9B20N008-EEntrepreneurship, FinanceOn November 14, 2017, Aurora Cannabis Inc. (Aurora) made a proposal to CanniMed Therapeutics Inc. (CanniMed) to acquire all of CanniMed’s issued and outstanding common shares in a share exchange that valued CanniMed’s common shares at a premium of almostStarting at €8.20
-
CanniMed Therapeutics: Acquiror or Target - Teaching Note
Stephen SappTeaching Note IVEY-8B20N008-EFinanceTeaching note for product 9B20N008.Starting at €0.00